Therefore, tumor BRCA1/2 testing is a powerful tool to identify mutations in ovarian cancer patients which have been shown to benefit from treatment with PARP inhibitors (Lheureux et al., 2017; Vergote et al., 2016). Here, BRCA1 is linked to neoplasm.